SCYNEXIS, Inc. reported its financial results for the second quarter ended June 30, 2025, on August 13, 2025. License agreement revenue for the quarter was $1.4 million, an increase from $0.7 million in the same period of 2024.
Research and development expenses increased by 5% to $7.1 million, primarily due to higher chemistry, manufacturing, and controls (CMC), preclinical, and clinical expenses. Selling, General and Administrative (SG&A) expenses increased by 20% to $3.8 million, mainly driven by higher professional fees.
The company reported a net loss of $6.9 million, or $(0.14) basic loss per share, for the quarter, which is an improvement from a net loss of $14.5 million, or $(0.30) basic loss per share, in the prior year period. Cash, cash equivalents, and investments totaled $46.5 million as of June 30, 2025, with management projecting a cash runway into Q4 2026.
SCYNEXIS continues to work towards resolving its dispute with GSK regarding milestone payments for the MARIO study. GSK has initiated the transfer of the New Drug Application for Brexafemme to them, indicating their commitment to its commercialization. The company also anticipates announcing SAD/MAD data from its Phase 1 study of oral SCY-247 in Q3 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.